PXDNL

Across TCGA pan-cancer cohorts, PXDNL RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PXDNL’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PXDNL RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PXDNL is over-expressed in tumor, although a few such as KIRP and KICH show the opposite, repressed pattern.

LIHC, KIRP, and HNSC are the cancer types where PXDNL tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PXDNL RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.546	<.001	9	view →
KIRP	Male	All	−1.596	<.001	8	view →
HNSC	Female	II,III,IV	+0.730	<.001	7	view →
KICH	Male	All	−1.017	.014	6	view →
THCA	All	II,III,IV	−0.345	.002	5	view →
BLCA	All	All	+0.185	.007	5	view →
BRCA	All	All	+0.556	<.001	4	view →
CHOL	All	All	+0.345	.020	4	view →
LUAD	All	II,III,IV	+0.328	.010	4	view →
LUSC	All	All	+0.290	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PXDNL–LIHC

Open the LIHC breakdown →